180 related articles for article (PubMed ID: 26986457)
1. Hypofractionated 3D radiotherapy for inoperable T1-3 N0-1 non-small-cell lung cancer.
Mollà M; Saez J; Ramos M; Giraldo A; Seoane A; Andreu J; Simó M; Giralt J
Br J Radiol; 2016 Jun; 89(1062):20150824. PubMed ID: 26986457
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25.
Cheung P; Faria S; Ahmed S; Chabot P; Greenland J; Kurien E; Mohamed I; Wright JR; Hollenhorst H; de Metz C; Campbell H; Vu TT; Karvat A; Wai ES; Ung YC; Goss G; Shepherd FA; O'Brien P; Ding K; O'Callaghan C
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25074417
[TBL] [Abstract][Full Text] [Related]
3. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy.
Thirion P; Holmberg O; Collins CD; O'Shea C; Moriarty M; Pomeroy M; O'Sullivan C; Buckney S; Armstrong J
Radiother Oncol; 2004 May; 71(2):163-6. PubMed ID: 15110449
[TBL] [Abstract][Full Text] [Related]
4. Inoperable early-stage primary and early recurrent non-small cell lung cancer: outcomes of a mono-institutional experience using a moderate hypofractionated schedule.
Valeriani M; Marinelli L; Reverberi C; De Sanctis V; Mollo D; Nicosia L; Osti MF
Radiol Med; 2019 Jan; 124(1):58-64. PubMed ID: 30178173
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer.
Cagney DN; Thirion PG; Dunne MT; Fleming C; Fitzpatrick D; O'Shea CM; Finn MA; O'Sullivan S; Booth C; Collins CD; Buckney SJ; Shannon A; Armstrong JG
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):30-38. PubMed ID: 29097074
[TBL] [Abstract][Full Text] [Related]
6. Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis.
Urbanic JJ; Turrisi AT; Sharma AK; Silvestri GA; Williams TE; Vanek KN; Sherman CA
J Thorac Oncol; 2006 Feb; 1(2):112-9. PubMed ID: 17409839
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
8. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
Rosenzweig KE; Fox JL; Yorke E; Amols H; Jackson A; Rusch V; Kris MG; Ling CC; Leibel SA
Cancer; 2005 May; 103(10):2118-27. PubMed ID: 15830346
[TBL] [Abstract][Full Text] [Related]
9. Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy.
Fang LC; Komaki R; Allen P; Guerrero T; Mohan R; Cox JD
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):108-16. PubMed ID: 16904517
[TBL] [Abstract][Full Text] [Related]
10. Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer.
Kepka L; Tyc-Szczepaniak D; Bujko K
J Thorac Oncol; 2009 Jul; 4(7):853-61. PubMed ID: 19487965
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated vs. conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy.
Iocolano M; Wild AT; Hannum M; Zhang Z; Simone CB; Gelblum D; Wu AJ; Rimner A; Shepherd AF
Acta Oncol; 2020 Feb; 59(2):164-170. PubMed ID: 31608751
[No Abstract] [Full Text] [Related]
12. [Relationship of dose-volume histogram parameters and computed tomography grading of radiation-induced lung injury in patients with non-small cell lung cancer treated by three-dimensional conformal radiotherapy].
Xing J; Li JB; Yu JM; Lu J; Xu M; Fan TY; Shao Q; Guo SF
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):676-81. PubMed ID: 19173909
[TBL] [Abstract][Full Text] [Related]
13. Definitive radiation therapy for stage I non-small-cell lung carcinoma: institutional experience with contemporary conformal planning.
Sandhu AP; Messer K; Fuster MM; Ahmad E; Pu M; Bazhenova L; Rose M; Seagren S
Clin Lung Cancer; 2009 Nov; 10(6):433-7. PubMed ID: 19900862
[TBL] [Abstract][Full Text] [Related]
14. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
[TBL] [Abstract][Full Text] [Related]
15. Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer.
Faria SL; Souhami L; Portelance L; Duclos M; Vuong T; Small D; Freeman CR
Radiat Oncol; 2006 Nov; 1():42. PubMed ID: 17078878
[TBL] [Abstract][Full Text] [Related]
16. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center.
Bush DA; Cheek G; Zaheer S; Wallen J; Mirshahidi H; Katerelos A; Grove R; Slater JD
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):964-8. PubMed ID: 23845845
[TBL] [Abstract][Full Text] [Related]
17. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy.
Belderbos JS; Heemsbergen WD; De Jaeger K; Baas P; Lebesque JV
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):126-34. PubMed ID: 16904518
[TBL] [Abstract][Full Text] [Related]
18. Survival and Toxicity of Hypofractionated Intensity Modulated Radiation Therapy in 4 Gy Fractions for Unresectable Stage III Non-Small Cell Lung Cancer.
Kong C; Zhu X; Shi M; Wang L; Chen C; Tao H; Jiang N; Yan P; Zhao L; Song X; He X
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):710-719. PubMed ID: 32275994
[TBL] [Abstract][Full Text] [Related]
19. Patient outcomes of monotherapy with hypofractionated three-dimensional conformal radiation therapy for stage T2 or T3 non-small cell lung cancer: a retrospective study.
Sakaguchi M; Maebayashi T; Aizawa T; Ishibashi N; Fukushima S; Abe O; Saito T
Radiat Oncol; 2016 Jan; 11():3. PubMed ID: 26781290
[TBL] [Abstract][Full Text] [Related]
20. Elective nodal failures are uncommon in medically inoperable patients with Stage I non-small-cell lung carcinoma treated with limited radiotherapy fields.
Bradley JD; Wahab S; Lockett MA; Perez CA; Purdy JA
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):342-7. PubMed ID: 12738307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
